TriCaprin Scientific Research Library
Peer-Reviewed Studies on C10 Triglycerides, TGCV, GLP-1 Muscle Loss, and Metabolic Health
The Osaka Origin Story
How a rare cardiac condition led researchers at Osaka University to discover tricaprin's role in heart muscle energy metabolism — and why it changed the direction of C10 research.
Read the Full Story →A Novel Clinical Entity: Triglyceride Deposit Cardiomyovasculopathy
This paper introduced TGCV as a newly recognized cardiovascular disease in which triglycerides accumulate inside the myocardium and coronary lesions because intracellular lipolysis is impaired.
Heart failure can result from a fuel-processing problem inside heart cells, not only from blocked arteries.
Triglyceride Deposit Cardiomyovasculopathy
A landmark early report that helped establish TGCV as a distinct clinical phenomenon tied to defective intracellular triglyceride breakdown.
TGCV helped shift attention from blood flow alone to energy metabolism inside heart muscle cells.
123I-BMIPP Scintigraphy Shows That CNT-01 (Tricaprin) Improves Myocardial Lipolysis in Patients With Idiopathic TGCV
This randomized, double-blind exploratory trial evaluated CNT-01, a tricaprin-based therapy, in patients with idiopathic TGCV.
CNT-01 improved myocardial lipolysis markers in a controlled human trial.
TriCaprin Rescues Myocardial Abnormality in a Mouse Model of Triglyceride Deposit Cardiomyovasculopathy
This preclinical study showed that tricaprin improved myocardial abnormalities in an ATGL-deficient mouse model of TGCV.
TriCaprin may help restore cardiac energy handling when long-chain fat metabolism is impaired.
Long-Term Survival and Durable Recovery of Heart Failure in Patients With TGCV Treated With TriCaprin
This study reported long-term survival and durable recovery of heart failure in patients with TGCV treated with tricaprin.
The findings suggest tricaprin may have clinically meaningful effects in this rare metabolic heart disease, though broader validation is still needed.
TriCaprin vs. MCT Oil — What the Difference Actually Means
Dietary Medium-Chain Triacylglycerols Suppress Accumulation of Body Fat in a Double-Blind, Controlled Trial in Healthy Men and Women
This study compared medium-chain triglycerides with long-chain fats and found greater thermogenesis and less body fat accumulation with MCT intake.
Medium-chain fats are metabolized differently from standard dietary fats.
Decanoic Acid Increases Mitochondrial Citrate Synthase Activity in Neuronal Cells
This work helped draw attention to the possibility that decanoic acid (C10) may influence mitochondrial enzyme activity directly.
C10 may do more than serve as fuel; it may also influence cellular energy machinery.
The Ketogenic Diet Fatty Acid Decanoic Acid Inhibits AMPA Receptors
This study showed that decanoic acid has direct pharmacological effects beyond ketone production.
C10 appears to have biologic effects that differ from C8.
Decanoic Acid Is a Direct PPARγ Ligand
This study explored how decanoic acid interacts with PPAR-γ, a receptor involved in glucose metabolism and insulin sensitivity.
C10 may influence metabolic signaling pathways relevant to insulin regulation.
Comparison of Native and Capric Acid-Enriched Mustard Oil Effects on Oxidative Stress and Antioxidant Protection in Rats
This study examined blood lipid and antioxidant effects associated with capric acid-enriched oils.
Capric acid may influence triglycerides, cholesterol, and oxidative stress markers in experimental settings.
Muscle Mass and GLP-1 Receptor Agonists: Adaptive or Maladaptive?
A high-profile review discussing lean mass changes in major GLP-1 trials including STEP-1 and SURMOUNT-1.
Lean mass loss during GLP-1 weight loss is now a major scientific and clinical debate.
Changes in Lean Body Mass With GLP-1 Therapies and Mitigation Strategies
This review quantifies lean mass loss across major GLP-1 trials and discusses possible ways to reduce it.
Preserving muscle during pharmacologic weight loss is becoming a core treatment goal.
GLP-1 Agonists on Body Composition: Systematic Review and Network Meta-Analysis
This review pooled data from 22 randomized trials and assessed how GLP-1 therapies affect fat and lean mass.
A meaningful share of weight loss can come from lean tissue, not just fat.
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
A broad review of how GLP-1 receptor agonists affect bone, muscle, and orthopedic outcomes.
GLP-1 drugs may reduce lean mass while also changing muscle composition and function.
Preservation of Lean Soft Tissue During Weight Loss Induced by GLP-1 and GLP-1/GIP Receptor Agonists: A Case Series
This case series showed that high protein intake and resistance training may help preserve lean mass during GLP-1-driven weight loss.
Muscle loss during GLP-1 therapy is not necessarily inevitable.
Once-Weekly Semaglutide in Adults With Overweight or Obesity
The foundational semaglutide obesity trial.
Semaglutide produced major weight loss and helped establish the modern GLP-1 obesity era.
Body Composition Changes During Weight Reduction With Tirzepatide
A body-composition substudy from SURMOUNT-1 using DXA measurements.
About 75% of lost weight was fat and about 25% was lean mass.
Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
A review focused on vulnerable populations such as older adults and patients with chronic disease.
Some groups may face higher functional risk from lean mass loss during GLP-1 treatment.
GLP-1 Receptor Agonists and Sarcopenia: Weight Loss at a Cost?
A narrative review discussing whether GLP-1 therapies may worsen sarcopenia risk and what future combination strategies may help.
Future obesity therapies may increasingly focus on preserving muscle while promoting fat loss.
GLP-1 Medications and Muscle Mass Preservation: Implications and Recommendations
A practical policy-oriented review covering protein intake, resistance training, and implementation guidance.
The muscle-preservation conversation is moving from theory into real-world policy and coaching guidance.
Important Note
This library is for educational purposes only.
It does not provide medical advice, diagnosis, or treatment recommendations.
This page will continue to be updated as new studies emerge.
